Evidence map›Paper›PMID 34970836›Full record

ArticleHIV medicine2022

The National Evaluation of Malawi's PMTCT Program (NEMAPP) study: 24-month HIV-exposed infant outcomes from a prospective cohort study.

Monique van Lettow, Beth A Tippett Barr, Joep J van Oosterhout, Erik Schouten, Andreas Jahn, Thokozani Kalua, Andrew Auld, Rose Nyirenda, Nellie Wadonda, Evelyn Kim and 1 more

Open access · hybridAbstract read
In one paragraph

Article in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Monique van LettowDignitas International, Zomba, Malawi.
Beth A Tippett BarrNyanja Health Research Institute, Salima, Malawi.
Joep J van OosterhoutDignitas International, Zomba, Malawi.
Erik SchoutenManagement Sciences for Health, Lilongwe, Malawi.
Andreas JahnMalawi Ministry of Health, Department of HIV and AIDS, Lilongwe, Malawi.
Thokozani KaluaMalawi Ministry of Health, Department of HIV and AIDS, Lilongwe, Malawi.
Andrew AuldUS Centers for Disease Control and Prevention, Lilongwe, Malawi.
Rose NyirendaMalawi Ministry of Health, Department of HIV and AIDS, Lilongwe, Malawi.
Nellie WadondaUS Centers for Disease Control and Prevention, Lilongwe, Malawi.
Evelyn KimUS Centers for Disease Control and Prevention, Lilongwe, Malawi.
Megan LandesDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Public Health Institute of Malawi · MWCenters for Disease Control and Prevention · UGDignitas International · MWPublic Health Ontario · CA

Funding

CGH CDC HHS U2G GH000721PEPFAR
6 · The paper itself

Abstract

objectivesData on long-term HIV-free survival in breastfeeding, HIV-exposed infants (HEIs) are limited. The National Evaluation of Malawi's Prevention of Mother-to-Child Transmission (PMTCT) Program (NEMAPP), conducted between 2014 and 2018, evaluated mother-to-child transmission (MTCT) and infant outcomes up to 24 months postpartum.

methodsWe enrolled a nationally representative cohort of HEIs at 54 health facilities across four regional strata in Malawi and used multivariable Cox regression analysis to investigate the risk of adverse outcomes (HIV transmission, infant death and loss to follow-up) to 24 months postpartum. Models, controlling for survey design, were fitted for the total cohort (n = 3462) and for a subcohort that received maternal viral load (VL) monitoring (n = 1282).

resultsBy 24 months, in 3462 HEIs, weighted cumulative MTCT was 4.9% [95% confidence interval (CI) 3.7-6.4%], 1.3% (95% CI 0.8-2.2%) of HEIs had died, 26.2% (95% CI 24.0-28.6%) had been lost to follow-up and 67.5% (95% CI 65.0-70.0%) were alive and HIV-free. Primiparity [weighted adjusted hazard ratio (aHR) 1.6; 95% CI 1.1-2.2; parity 2-3: weighted aHR 1.5; 95% CI 1.2-1.9], the mother not disclosing her HIV status to her partner (no disclosure: weighted aHR 1.3; 95% CI 1.1-1.6; no partner: weighted aHR 0.7; 95% CI 0.5-0.9), unknown maternal ART start (weighted aHR 2.0; 95% CI 1.0-3.9) and poor adherence (missed ≥ 2 days of ART in the last month: weighted aHR 1.7; 95% CI 1.2-2.2; not on ART: weighted aHR 1.7; 95% CI 1.0-2.7) were associated with adverse outcomes by 24 months. In the subcohort analysis, risk of HIV transmission or infant death was higher among HEIs whose mothers started ART post-conception (during pregnancy: weighted aHR 3.2; 95% CI 1.3-7.7; postpartum: weighted aHR 12.4; 95% CI 1.5-99.6) or when maternal viral load at enrolment was > 1000 HIV-1 RNA copies/mL (weighted aHR 15.7; 95% CI 7.8-31.3).

conclusionsInfant positivity and infant mortality at 24 months were low for a breastfeeding population. Starting ART pre-conception had the greatest impact on HIV-free survival in HEIs. Further population-level reduction in MTCT may require additional intervention during breastfeeding for women new to PMTCT programmes. Pre-partum diagnosis and linkage to ART, followed by continuous engagement in care during breastfeeding can further reduce MTCT but are challenging to implement.

Indexed as

HIV InfectionsPregnancy Complications, InfectiousCohort StudiesFemaleHumansInfantInfant DeathInfectious Disease Transmission, VerticalMalawiPregnancyProspective StudiesdisclosureHIV-exposed infantsHIV-free survivalMalawimother-infant pairsOption B+prevention of mother-to-child transmissiontreat all

Identifiers

PMID34970836
PMCPMC9303195
OpenAlexW4206635217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.